유럽 연합 - 몰타어 - EMA (European Medicines Agency)

intervet international b.v. - Ċirovirus tal-porċini tat-tip 2 ta 'l-antiġen tat-tip subunit orf2 - immunologicals for suidae, inactivated viral vaccines - majjali - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection.  to reduce loss of daily weight gain and mortality associated with pcv2 infection.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

laboratorios hipra, s.a. - verotoxin 2e rikombinanti ta 'e. coli - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium, immunologicals for suidae - majjali - immunizzazzjoni attiva ta 'ħnieżer minn jumejn biex tevita l-mortalità u tnaqqas sinjali kliniċi ta' mard ta 'edema (ikkawżat minn verotossina 2e prodotta minn e. coli) u biex jitnaqqas it-telf ta 'żieda fil-piż ta' kuljum matul il-perjodu ta 'l-irfinar quddiem infezzjonijiet bil-verotossina 2e li tipproduċi e. coli sal-qatla mill-età ta '164 jum.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - chicken - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

zoetis belgium sa - ċirkovirus tal-ħnieżer-vaċċin (inattivat, rikombinanti) - immunologicals for suidae, inactivated viral vaccines - Ħnieżer (għall-tismin) - għall-immunizzazzjoni attiva tal-ħnieżer mill-età ta ' 3 ġimgħat kontra l-virus porcine circovirus tip 2 (pcv2) biex titnaqqas it-tagħbija virali fid-demm u fit-tessuti linfojde u l-ippurgar jixħtu kkawżati mill-infezzjoni bil-pcv2.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - infezzjonijiet pnewmokokkali - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. ara t-taqsimiet 4. 4 u 5. 1 għal informazzjoni dwar il-protezzjoni kontra serotipi pnewmokokkiċi speċifiċi. the use of vaxneuvance should be in accordance with official recommendations.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

elanco gmbh - escherichia coli ħajjin mhux patoġeniċi o141: k94 (f18ac) u o8: k87 (f4ac) - immunologicals for suidae, live bacterial vaccines - majjali - għall-immunizzazzjoni attiva tal-majjali minn 18-il jum ta'l-età kontra l-enterotoxigenic f4-pożittivi u f18-pożittivi escherichia coli sabiex titnaqqas l-inċidenza ta moderat għal sever ta ' wara l-ftim e. coli diarrhea (pwd) fil-ħnieżer infettati u biex jitnaqqas it-tixrid tal-feċi ta 'e-enterotoxigenic f4 pożittiv u e pożittiv f18. coli minn ħnieżer infettati.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

ceva santé animale - vaċċin inattivat ta 'coxiella burnetii, strain nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - clostridium tetani toxoid / kvp 2242 virus / vcp1529 virus / għal vcp1533 għal virus / vcp3011 virus - immunologicals for equidae, live viral and inactivated bacterial vaccines, equine influenza virus + clostridium - Żwiemel - immunizzazzjoni attiva ta 'żwiemel ta' erba 'xhur jew akbar kontra l-influwenza taż-żwiemel biex jitnaqqsu s-sinjali kliniċi u l-eskrezzjoni tal-virus wara infezzjoni, u kontra t-tetnu biex tiġi evitata l-mortalità.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, sheep, inactivated viral vaccines - nagħaġ - immunizzazzjoni attiva tan-nagħaġ minn 1. 5 xhur għall-prevenzjoni tal-viremija kkawżata mill-virus tal-bluetongue, is-serotipi 1 u 8. il-bidu tal-immunità: 21 jum wara t-tlestija tal-iskema ta 'tilqim primarju. tul ta 'żmien tal-immunità: 12-il xahar.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

cz veterinaria s.a. - bluetongue virus vaccine serotypes 1 or 4 or 8 [inactivated] - immunoloġiċi - sheep; cattle - sheepactive-tilqim kontra l-virus tal-bluetongue tas-serotip 8 għall-prevenzjoni kontra viremja u biex tnaqqas sinjali kliniċi. il-bidu tal-immunità: 20 jum wara t-tieni doża. tul ta 'żmien tal-immunità: sena wara t-tieni doża. cattleactive-tilqim kontra l-virus tal-bluetongue tas-serotip 8 għall-prevenzjoni kontra viremja. il-bidu tal-immunità: 31 jum wara t-tieni doża. tul ta 'żmien tal-immunità: sena wara t-tieni doża.